Cancer – Research Ideas, Questions, and Suggestions (CRIQS) – 3 (eBook cover)
This article has some points from 3rd edition of eBook “CRIQS (Cancer – Research Ideas, Questions, and Suggestions)”.
Cancer is the second most important cause of death in the U.S., and would soon surpass deaths caused by heart diseases. In men, prostate, lung and bronchus, and colorectal cancers account for about 50% of cases, whereas in women, breast, lung and bronchus, and colorectum cancers account for about 50% of cases.
In cancer research, most commonly studied organs are breast, lung, and prostate, and chemotherapy is most commonly studied therapeutic strategy. In the past few years, scientists have started giving increased level of consideration to advanced forms of cancer.
One of the most important issues in cancer research is that very few percentage of cancer patients (you can see the percentage in the eBook) actually take part in cancer research.
In the research on cancer, we can use some methods/instruments/processes such as acoustic-based microfluidic device, genome-wide expression profiling, immunohistochemical assessment, Reverse transcription polymerase chain reaction (RT-PCR), and sequencing technology. We can also take the help of certain software or packages such as various R-packages (you can find the examples of R-packages in the eBook.)
Cancer stem cells, making about 5% of a tumor, have the ability to live even after treatment with chemotherapy or radiation. These cells are thought to be resistant to most of the conventional therapies. They can spread the cancer to other areas. On a further note, cancer cells can develop an ability to deceive the immunity by hiding from the immune system. Moreover, they may use the cells of the immune system to live and grow.
These are some of the points from the eBook “CRIQS (Cancer – Research Ideas, Questions, and Suggestions)”. You can find a number of research ideas, questions, and suggestions in the eBook.
Your purchase of the eBook will help me in doing more research on cancer.